H.C. Wainwright analyst Andrew Fein upgraded Terns Pharmaceuticals (NASDAQ: TERN) from Neutral to Buy with a price target of $20.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE